Floatz logo

DICLOFENAC

Colo-rectal Cancer

Zealand University HospitalSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Colo-rectal Cancer cohort.

Asset / SponsorPhaseRating
Pentoxifylline
Tanta University
Phase 2BB
Dkn-01
Leap Therapeutics, Inc.
Phase 2B
Naproxen
M.D. Anderson Cancer Center
Phase 2CCC
Dalmitamig
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
vv1
Vyriad, Inc.
Phase 2CCC

View all 20 →

Same molecule, other indications

DICLOFENAC is also rated in:

arthropathyDormant
BBB
Indicative ·
73 / 100
View asset →
Surgical Wound InfiltrationDormant
BB
Indicative ·
69 / 100
View asset →
Lymph Node DissectionDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →